RT Journal Article
SR Electronic
T1 55 Quality of life is similar in patients with chronic stable heart failure on either vasodilating or non-vasodilating beta blockers. modified kansas city cardiomyopathy questionnaire
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP A32
OP A32
DO 10.1136/heartjnl-2017-ICS17.55
VO 103
IS Suppl 6
A1 R Pharithi
A1 E Egom
A1 A Maher
A1 S Fall
A1 S Fahy
A1 A Jago
A1 T Mannion
A1 L Delaney
A1 B Khan
A1 I Yearoo
A1 C Murphy
A1 V Maher
YR 2017
UL http://heart.bmj.com/content/103/Suppl_6/A32.1.abstract
AB Background Beta-blockers with additional nitric oxide-mediated vasodilating properties are beneficial in patients with heart failure but its unknown if they are better than non-vasodilating Beta blockers.Aim To compare quality of life in patients with chronic heart failure stabilised on vasodilating and non-vasodilating beta-blockers.Methods and Results 163 patients having chronic stable heart failure for at least 6 months were evaluated according to their treatment with vasodilating or non-vasodilating betablockers. Modified Kansa city cardiomyopathy score was used to assess quality of life. Table 1 summarises patient characteristics, comorbidities and parameters of quality of life in both groups.View this table:Abstract 55 Table 1 Patient characteristics, comorbidities and parameters of quality of lifeConclusion There was no difference in the quality of life of patients on vasodilating and non-vasodilating beta-blockers. While vasodilation should improve quality of life, the lack of difference in our study may reflect that patients may already have maximal vasodilation due to their other therapeutic agents such as ACE or ARBs. This indicates that beta blocker choice is not essential in otherwise optimally treated patients.